Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease

Circulation Journal

Volumn 72, Issue 12, 2008, Pages 2046-2050

  Matsuo, Yoshiki ^a   Hashizume, Toshikazu ^a   Shioji, Shusaku ^a   Akasaka, Takashi ^b  

^a National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; Low density lipoprotein cholesterol; Metabolic syndrome; Secondary prevention

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INFLAMMATION; JAPAN; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OBESITY; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 56849087900     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0337     Document Type: Article

References (23)

1. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.
2. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: An analysis of the PROVEIT TIMI-22 trial. J Am Coll Cardiol 2005; 45: 1644-1648.
3. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114: 281-288.
4. Matsuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Jpn Soc Int Med 2005; 94: 188-203.
5. IPAQ Research Committee: International physical activity questionnaire: Short last 7 days self-administered format (November 2005). Available from http://www.ipaq.ki.se (accessed 14 February, 2008).
6. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardio vascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
7. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183-1190.
8. Oda E, Oohara K, Abe A, Veeraveedu PT, Watanabe K, Kato K, et al. The optimal cut-off point of C-reactive protein as an optional component of metabolic syndrome in Japan. Circ J 2006; 70: 384-388.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
10. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: The Minoh Study. Circ J 2005; 69: 386-391.
11. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kajii E. Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ J 2007; 71: 26-31.
12. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: A population-based study. Diabetes Care 2000; 23: 1835-1839.
13. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145-150.
14. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
15. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
16. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
17. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Hazen SL, Ntanios F, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006; 97: 1553-1557.
18. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
19. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, et al; Women's Ischemia Syndrome Evaluation Investigators. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109: 714-721.
20. Kasai T, Miyauchi K, Kurata T, Ohta H, Okazaki S, Miyazaki T, et al. Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J 2006; 70: 1531-1537.
21. Wassink AM, van der Graaf Y, Olijhoek JK, Visseren FL; SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008; 29: 213-223.
22. Messerli AW, Seshadri N, Pearce GL, Sachar R, Hoogwerf BJ, Sprecher DL. Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome. Am J Cardiol 2003; 92: 610-612.
23. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.